JP2023549196A5 - - Google Patents

Info

Publication number
JP2023549196A5
JP2023549196A5 JP2023528189A JP2023528189A JP2023549196A5 JP 2023549196 A5 JP2023549196 A5 JP 2023549196A5 JP 2023528189 A JP2023528189 A JP 2023528189A JP 2023528189 A JP2023528189 A JP 2023528189A JP 2023549196 A5 JP2023549196 A5 JP 2023549196A5
Authority
JP
Japan
Prior art keywords
inhibitor
oral
combination
methoxyurea
tetrahydrothieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081304 external-priority patent/WO2022101303A1/en
Publication of JP2023549196A publication Critical patent/JP2023549196A/ja
Publication of JP2023549196A5 publication Critical patent/JP2023549196A5/ja
Pending legal-status Critical Current

Links

JP2023528189A 2020-11-11 2021-11-10 レルゴリクスの投与方法 Pending JP2023549196A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112523P 2020-11-11 2020-11-11
US63/112,523 2020-11-11
US202163151423P 2021-02-19 2021-02-19
US63/151,423 2021-02-19
PCT/EP2021/081304 WO2022101303A1 (en) 2020-11-11 2021-11-10 Methods of administering relugolix

Publications (2)

Publication Number Publication Date
JP2023549196A JP2023549196A (ja) 2023-11-22
JP2023549196A5 true JP2023549196A5 (enExample) 2024-11-15

Family

ID=78709420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528189A Pending JP2023549196A (ja) 2020-11-11 2021-11-10 レルゴリクスの投与方法

Country Status (3)

Country Link
EP (1) EP4243829A1 (enExample)
JP (1) JP2023549196A (enExample)
WO (1) WO2022101303A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
US9949974B2 (en) * 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) * 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
SG11201911598WA (en) * 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US20190054088A1 (en) * 2017-08-18 2019-02-21 Abbvie Inc. Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Similar Documents

Publication Publication Date Title
JP2023549196A5 (enExample)
KR101812160B1 (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
JP2012502988A (ja) 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法
TW200831107A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
JP2005514345A (ja) 更年期以降の女性生殖機能障害の治療のための組成物
JP2007512291A (ja) ２種のエストロゲン及び／又はプロゲスチン組成物を含んで成る、２１〜２８日よりも長い期間にわたっての連続ホルモン処理のための医薬製剤
HU221583B (hu) Térhálósított, polikarbonsavalapú polimer alkalmazása progeszteront tartalmazó vaginális gyógyszerkészítmény előállítására
TW201201799A (en) Parenteral dosage form releasing aromatase inhibitors and progestins to treat endometriosis
JP2005515964A (ja) ホルモン欠乏症を治療するための治療用組成物
US20050101579A1 (en) Endometriosis treatment protocol
FI3634419T3 (fi) Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi
WO2003017973A1 (en) A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
CA2601773A1 (en) Compositions of unconjugated estrogens and methods for their use
JP2004519490A (ja) エキセメスタンによるホルモン依存性異常症の組合せ治療方法
US20040082557A1 (en) Methods for treating estrogen-dependent disorders
KR20000048981A (ko) 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진 호르몬 조성물
CA2582530A1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TWI354556B (en) Use of a combination of an aromatase inhibitor,a p
US20040142914A1 (en) Extended transdermal contraceptive regimens
KR100772852B1 (ko) 자궁내막증 치료용 약제학적 조성물
JP2004529176A (ja) 頸管熟化を誘導するためのホスホジエステラーゼインヒビターを含む組成物
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
TW200904452A (en) New drospirenone/17β-estradiol regimen, pharmaceutical combination, product and kit for performing this regimen
US11446351B2 (en) Composition for treating one or more estrogen related diseases
JP2001523639A (ja) プロゲストゲン−抗プロゲストゲンレジメン